Drug intelligence / Profile preview

phleum pratense allergoid

Development stage
Phase 2
Lead developer
HAL Allergy
Modality
Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Intradermal, Subcutaneous
01

Overview

Phleum pratense allergoid is a chemically modified **allergen immunotherapy** product derived from *Phleum pratense* pollen, developed in the cited clinical studies by **LETI Pharma** for treatment of grass pollen allergy, particularly allergic rhinitis, rhinoconjunctivitis, and allergic asthma. The active substance is a **depigmented, glutaraldehyde-polymerized pollen extract** designed to reduce IgE-mediated allergenicity while preserving T-cell immunogenicity, enabling repeated administration by subcutaneous or intradermal injection. In randomized placebo-controlled studies, this allergoid reduced combined symptom and medication scores and improved conjunctival provocation tolerance, supporting its use as a disease-modifying allergen-specific immunotherapy rather than a symptomatic anti-allergy drug.

Brand names
Depigoid Phleum pratense
Other names
phleum pratense allergoidp. pratense allergoiddepigmented and polymerized allergen extract of phleum pratensedepigmented, polymerised extract of phleum pratense pollenglutaraldehyde-polymerized phleum pratense extractdepigmented glutaraldehyde-polymerized therapeutic vaccine of phleum pratense
02

Targets

Timothy grass-specific IgE (Timothy grass-specific immunoglobulin E)Allergen-specific IgG antibodies against Phleum pratense pollen proteinsT cell receptor recognizing Phleum pratense peptides presented on MHC

Beyond the preview

Go deeper on phleum pratense allergoid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on phleum pratense allergoid.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call